Characterisation of clinically relevant sympathomimetics;Grundsatze der katecholamin-therapie teil 1: Charakterisierung der therapeutisch bedeutsarnen Sympathomimetika

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 35, Issue 2, 2000, Pages 67-81

  Schutz W ^a   Anhaupl T ^a   Gauss, A ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Catecholamines; Receptors, adrenergic, alpha, beta, dopamine; Sympathetic nervous system

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CYCLIC AMP; DOBUTAMINE; DOPAMINE; DOPEXAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; NORADRENALIN; ORCIPRENALINE; PHOSPHODIESTERASE INHIBITOR;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; CHOLINERGIC SYSTEM; DRUG EFFECT; HEART RATE; HEART STROKE VOLUME; INOTROPISM; REVIEW; SPLANCHNIC BLOOD FLOW; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; HUMAN; PHYSIOLOGY;

ANIMALS; CATECHOLAMINES; HUMANS; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOMIMETICS;

EID: 0034132130     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-10848     Document Type: Review

References (121)

1. Lewandowsky M: Über eine Wirkung des Nebennierenextraktes auf das Auge. Zent. Bl. Physiol. 1898; 12: 599-600
2. Oliver G, Schafer EA: The physiological effects of extracts of the suprarenal capsules. J. Physiol. 1895; 18: 230-276
3. Baumann E: Intrakardiale Adrenalininjektion bei akuter Herzlähmung. Schweiz. Med. Wochenschr. 1923; 53: 198-200
4. Ahlquist RP: A study of the adrenotropic receptors. Am. J. Physiol. 1948; 153: 586-600
5. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG: Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597-598
6. Smiley RM, Kwatra MM, Schwinn DA: New developments in cardiovascular adrenergic receptor pharmacology: Molecular mechanisms and clinical relevance. J. Cardiothorac. Vasc. Anesth. 1998; 12: 80-95
7. Starke K: Pharmakologie noradrenerger und adrenerger Systeme. In: Forth W, Henschler D, Rummel W, Starke K (Hrsg.): Allgemeine und spezielle Pharmakologie und Toxikologie; 7. Aufl. Spektrum Heidelberg. 1996: 161-200
8. Lefkowitz RJ, Hoffman BB, Taylor P: Neurotransmission. In: Hardman JG, Goodman Gilman A, Limbird LE (Hrsg.): Goodman & Gilman's The Pharmacological Basis of Therapeutics; 9. Aufl. McGraw-Hill New York. 1995: 105-140
9. Insel PA: Adrenergic receptors - evolving concepts and implications. N. Engl. J. Med. 1996; 334: 580-585
10. 1-Adrenoceptors: an overview. Pharmacol. Rev. 1993; 45: 147-175
11. Brodde O-E: Stellenwert der myokardialen Adrenozeptoren und ihre Bedeutung für die Therapie. In: Pasch T, Schmid ER (Hrsg.): Anästhesie und kardiovaskuläres System (Klinische Anästhesiologie und Intensivtherapie); Bd. 41 Springer Berlin. 1991: 72-80
12. 3-adrenoceptor in man. Br. J. Pharmacol. 1993; 110: 929-936
13. Lee MR: Dopamine and the kidney: ten years on. Clin. Sci. 1993; 84: 357-375
14. Olsen NV, Lund J, Jensen PF, Espersen K, Kanstrup IL, Plum I, Leyssac PP: Dopamine, dobutamine, and dopexamine: A comparison of renal effects in unanesthetized human volunteers. Anesthesiology 1993; 79: 685-694
15. Orme ML'E, Breckenridge A, Dollery CT: The effects of long term administration of dopamine on renal function in hypertensive patients. Eur. J. Clin. Pharmacol. 1973; 6: 150-155
16. Melmon KL: The endocrinologic function of selected autacoids: Catecholamines, acetylcholine, serotonin, and histamine. In: Williams RH (Hrsg.): Textbook of Endocrinology; 6. Aufl. W.B. Saunders Philadelphia. 1981: 515-588
17. Lefkowitz RJ, Coteccia S, Samama P, Costa T: Constitutive activity of receptors coupled to guanin nucleotide regulatory proteins. Trends Pharmacol. Sci. 1993; 14: 303-307
18. 2-adrenergic receptor. Mol. Pharmacol. 1994; 45: 390-394
19. Schwinn DA: Adrenoceptors as models for G protein-coupled receptors: structure, function and regulation. Br. J. Anaesth. 1993; 71: 77-85
20. Gilman AG: G proteins and dual control of adenylate cyclase. Cell 1984; 35: 577-579
21. Gierschik P, Grandt R, Marquetant R, Jakobs KH: Role of G-proteins in signal transduction. J. Cardiovasc. Pharmacol. 1987; 10 (Suppl. 4): 6-10
22. Gilman AG: G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 1987; 56: 615-649
23. Neer EJ, Clapham DE: Roles of G protein subunites in transmembrane signaling. Nature 1988; 333: 129-134
24. Freissmuth M, Casey PJ, Gilman AG: G proteins control diverse pathways of transmembrane signaling. FASEB J. 1989; 3: 2125-2130
25. Sutherland EW, Robinson GA, Butcher RW: Some aspects of the biological role of adenosine 3,5-monophosphate (cycl.-AMP). Circulation 1968; 37: 279-306
26. Hers HG, vanSchaftingen E: Fructose 2,6-bisphosphate two years after its discovery. Biochem. J. 1980; 206: 1-12
27. Reuter H: Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 1983; 301: 569-574
28. Hausdorff WP, Caron MG, Lefkowitz RJ: Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J. 1990; 4: 2881-2889
29. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ: β-Arrestin: A protein that regulates β-adrenergic receptor function. Science 1990; 248: 1547-1550
30. Bristow MR, Hershberger RA, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Gates AE, Feldman AM: β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82 (Suppl. I): 112-1 25
31. Collins S, Caron MG, Lefkowitz RJ: Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression. Annu. Rev. Physiol. 1991; 53: 497-508
32. Aarons RD, Molinoff PB: Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J. Pharmacol. Exp. Ther. 1982; 221: 439-443
33. Brodde O-E: Prinzipien der rationalen Katecholamintherapie. In: Radke J (Hrsg.): Refresher Course. Aktuelles Wissen für Anästhesisten. Springer Berlin. 1995: 89-102
34. Cohn JN: Drug therapy: The management of chronic heart failure. N. Engl. J. Med. 1996; 335: 490-498
35. Bristow MR, Gilbert EM: Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur. Heart J. 1995; 16 (suppl. F): 20-31
36. Collins S, Caron MG, Lefkowitz RJ: β-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J. Biol. Chem. 1988; 263: 9067-9070
37. 2-adrenergic receptor gene in response to short term agonist exposure. Proc. Natl. Acad. Sci. 1989; 86: 4853-4857
38. Saito T, Takanashi M, Gallagher E, Fuse A, Suzaki S, Inagaki O, Yamada K, Ogawa R: Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995; 21: 204-210
39. 125Iodocyanopindolol in human mononuclear leucocytes duringepinephrine infusion. J. Recept. Res. 1993; 13: 355-367
40. Kaufmann TM, Horton JW: Characterization of cardiac β-adrenergic receptors in the guinea pig heart: application to study of β-adrenergic receptors in shock models. J. Surg. Res. 1993; 55: 516-523
41. Booth JV, Landolfo KP, Chesnut LC, Bennett-Guerrero E, Gerhardt MA, Atwell MD, EI-Moalem HE, Smith MS, Funk BL, Kuhn CM, Kwatra MM, Schwinn DA: Acute depression of myocardial β-adrenergic receptor signaling during cardiopulmonary bypass -impairment of the adenylyl cyclase moiety. Anesthesiology 1998; 89: 602-611
42. Schwinn DA, Leone BJ, Spahn DR, Chesnut LC, Page SO, McRae RL, Liggett SB: Desensitization of myocardial β-adrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation. Circulation 1991; 84: 2559-2567
43. Werdan K: Towards a more causal treatment of septic cardiomyopathy. In: Vincent J-L (Hrsg.): Yearbook of Intensive Care and Emergency Medicine. Springer Berlin. 1995: 517-538
44. Romano FD, Jones SB: Alterations in β-adrenergic stimulation of myocardial adenylate cyclase in endotoxic rats. Am. J. Physiol. 1986; 250: R358-R364
45. 2-adrenergic responses. Circ. Shock 1993; 39: 275-278
46. 1-adrenoceptors in kitten myocardium. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989; 339: 113-128
47. Brown L, Deighton NM, Bals S, Söhlmann W, Zerkowski H-R, Michel MC, Brodde O-E: Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J. Cardiovasc. Pharmacol. 1992; 19: 222-232
48. Kaumann AJ, Lemoine H, Schwederski-Menke U, Ehle B: Relations between β-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989; 339: 99-112
49. Prielipp RC, MacGregor DA, Royster RL, Kon ND, Hines MH, Butterworth JF: Dobutamine antagonizes epinephrine's biochemical and cardiotonic effects. Anesthesiology 1998; 89: 49-57
50. Dale HH: On some physiologic actions of ergot. J. Physiol. 1906; 35: 163-206
51. Steen PA, Tinker JH, Pluth JR, Barnhorst DA, Tarhan S: Efficacy of dopamine, dobutamine, and epinephrine during emergence from cardiopulmonary bypass in man. Circulation 1978; 57: 378-384
52. Giraud GD, MacCannell KL: Decreased nutrient blood flow during dopamine-and epinephrine-induced intestinal vasodilatation. J. Pharmacol. Exp. Ther. 1984; 230: 214-220
53. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L: Epinephrine impairs splanchnic perfusion in septic shock. Crit. Care Med. 1997; 25: 399-404
54. Levy B, Bollaert P-E, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A: Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med. 1997; 23: 282-287
55. Robertson C, Steen P, Adgey J, Bossaert L, Carli P, Chamberlain D, Dick W, Ekstrom L, Hapnes SA, Holmberg S, Juchems R, Kette F, Koster R, deLatorre FJ, Lindner K, Perales N: The 1998 European Resuscitation Council guidelines for adult advanced life support. Resuscitation 1998; 37: 81-90
56. Nadkarni V, Hazinski MF, Zideman D, Kattwinkel J, Quan L, Bingham R, Zaritsky A, Bland J, Kramer E, Tiballs J: Paediatric life support. An advisory statement by the paediatric life support working group of the international liaison committee on resuscitation. Resuscitation 1997; 34: 115-127
57. MacGregor DA, Prielipp RC, Butterworth JF, James RL, Royster RL: Relative efficacy and potency of β-adrenoceptor agonists for generating cAMP in human lymphocytes. Chest 1996; 109: 194-200
58. Redl-Wenzl EM, Armbruster C, Edelmann G, Fischl E, Kolacny M, Wechsler-Fördös A, Sporn P: The effects of norepinephrine on hemodynamics and renal fanction in severe septic shock states. Intensive Care Med. 1993; 19: 151-154
59. Meadows D, Edwards JD, Wilkins RG, Nightingale P: Reversal of intractable septic shock with norepinephrine therapy. Crit. Care Med. 1988; 16: 663-666
60. Martin C, Perrin G, Saux P, Papazian L, Gouin F: Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med. 1994; 20: 444-447
61. Zhang H, Smail N, Cabral A, Rogiers P, Vincent J-L: Effects of norepinephrine on regional blood flow and oxygen extraction capabilities during endotoxic shock. Am. J. Respir. Crit. Care Med. 1997; 155: 1965-1971
62. Marik PE, Mohedin M: The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. J. Am. Med. Ass. 1994; 272: 1354-1357
63. Meier-Hellmann A, Reinhart K: Effects of catecholamines on regional perfusion and oxygénation in critically ill patients. Acta Anaesthesiol. Scand. 1995; 39 (Suppl. 107): 239-248
64. Hoffman BB, Lefkowitz RJ: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Goodman Gilman A, Limbird LE (Hrsg.): Goodman & Gilman's The Pharmacological Basis of Therapeutics; 9. Aufl. McGraw-Hill New York. 1995: 199-248
65. Schaer GL, Fink MP, Parrillo JE: Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit. Care Med. 1985; 13: 492-496
66. Richer M, Robert S, Lebel M: Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit. Care Med. 1996; 24: 1150-1156
67. Juste RN, Panikkar K, Soni N: The effects of low-dose dopamine infusion on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline. Intensive Care Med 1998; 24: 564-568
68. Prewitt RM: Hemodynamic management in pulmonary embolism and acute hypoxemic respiratory failure. Crit. Care Med. 1990; 18: 61-69
69. Neidhart P, Fuchs T: Anästhesiologische und therapeutische Besonderheiten bei Rechtsherzinsuffizienz. In: Pasch T, Schmid ER (Hrsg.): Anästhesie und kardiovaskuläres System (Klinische Anästhesiologie und Intensivtherapie, Bd. 41). Springer Berlin. 1991: 93-100
70. Tarnow J: Anaesthesie und Kardiologie in der Herzchirurgie. Springer Berlin. 1983
71. Laver MB: Myocardial ischaemia. Dilemma between information available and information demand. Br. Heart J. 1983; 50: 223-230
72. Hess W, Klein W, Mueller-Busch C, Tarnow J: Haemodynamic effects of dopamine and dopamine combined with nitroglycerin in patients subjected to coronary bypass surgery. Br. J. Anaesth. 1979; 51: 1063-1069
73. Gabel JC: Dopamine: do the risks outweigh the benefits? In: Lawin P, Peter K, Prien T (Hrsg.): Intensivmedizin 1995: Praxis der Intensivbehandlung (Schriftenreihe Intensivmedizin, Notfallmedizin, Anästhesiologie; Bd. 85). Thieme Stuttgart. 1995: 78-90
74. Duke GJ, Bersten AD: Dopamine and renal salvage in the critically ill patient. Anaesth. Intens. Care 1992; 20: 277-302
75. Hilberman M, Maseda J, Stinson EB, Derby GC, Spencer RJ, Miller DC, Oyer PE, Myers BD: The diuretic properties of dopamine in patients after open-heart operation. Anesthesiology 1984; 61: 489-494
76. Vendegna TR, Anderson RJ: Are dopamine and/or dobutamine renoprotective in intensive care unit patients? Crit. Care Med. 1994; 22: 1893-1894
77. Duke GJ, Briedis JH, Weaver RA: Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit. Care Med. 1994; 22: 1919-1925
78. Lherm T, Troche G, Rossignol M, Bordes P, Zazzo JF: Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med. 1996; 22: 213-219
79. Swygert TH, Roberts LC, Valek TR, Brajtbord D, Brown MR, Gunning TC, Paulsen AW, Ramsay MA: Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesioloy 1991; 75: 571-576
80. Baldwin L, Henderson A, Hickman P: Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery. Ann. Intern. Med. 1994; 120: 744-747
81. Myles PS, Buckland MR, Schenk NJ, Cannon GB, Langley M, Davis BB, Weeks AM: Effect of "renal dose" dopamine on renal function following cardiac surgery. Anaesth. Intens. Care 1993; 21: 56-61
82. Thompson BT, Cockrill BA: Renal-dose dopamine: a siren song? Lancet 1994; 344: 7-8
83. Szerlip HM: Renal-dose dopamine: fact and fiction. Ann. Intern. Med. 1991; 115: 153-154
84. Vincent J-L: Renal effects of dopamine: can our dream ever come true? Crit. Care. Med. 1994; 22: 5-6
85. Kindgen-Milles D, Tarnow J: Niedrig dosiertes Dopamin verbessert die Nierenfunktion: Derzeitiger Kenntnisstand und Bewertung einer kontroversen Diskussion. Anästh. Intensivmed. Notfallmed. Schmerzther. 1997; 32: 333-342
86. van den Berghe G, de Zegher F, Lauwers P: Dopamine suppresses pituitary function in infants and children. Crit. Care Med. 1994; 22: 1747-1753
87. van den Berghe G, de Zegher F: Anterior pituitary function during critical illness and dopamine treatment. Crit. Care Med. 1996; 24: 1580-1590
88. Devins SS, Miller A, Herndon BL, O'Toole L, Reisz G: Effects of dopamine on T-lymphozyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit. Care Med. 1992; 20: 1644-1649
89. Munn J, Tooley M, Bolsin S, Hronek I, Lowson S, Willcox J: Effect of metoclopramide on renal vascular resistance index and renal function in patients receiving a low-dose infusion of dopamine. Br. J. Anaesth. 1993; 71: 379-382
90. Niemer M: Herz und Kreislauf. In: Niemer M, Nemes C, Lundsgaard-Hansen P, Blauhut B (Hrsg.): Datenbuch Intensivmedizin; 3. Aufl. Gustav Fischer Stuttgart. 1992: 365-727
91. Meier-Hellmann A, Bredle DL, Specht M, Spies C, Hannemann L, Reinhart K: The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med. 1997; 23: 31-37
92. Williams JF, Bristow MR, Fowler MB, Francis GS, Garson A, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters WL: Guidelines for the evaluation and management of heart failure. Circulation 1995; 92: 2764-2784
93. Nevière R, Mathieu D, Chagnon J-L, Lebleu N, Wattel F: The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am. J. Respir. Crit. Care Med. 1996; 154: 1684-1688
94. Levy B, Bollaert P-E, Lucchelli J-P, Sadoune L-O, Nace L, Larcan A: Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit. Care Med. 1997; 25: 1649-1654
95. Reinhart K, Meier-Hellmann A, Hannemann L: Regional versus global indicators of tissue oxygenation. In: Vincent J-L (Hrsg.): Yearbook of Intensive Care and Emergency Medicine. Springer Berlin. 1994: 191-199
96. Ruokonen E, Uusaro A, Alhava E, Takala J: The effect of dobutamine infusion on splanchnic blood flow and oxygen transport in patients with acute pancreatitis. Intensive Care Med. 1997; 23: 732-727
97. Parviainen I, Ruokonen E, Takala J: Dobutamine-induced dissociation between changes in splanchnic blood flow and gastric intramucosal pH after cardiac surgery. Br. J. Anaesth. 1995; 74: 277-282
98. Smith GW, O'Connor SE: An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). Am. J. Cardiol. 1988; 62: 9C-17C
99. 2 adrenoceptors in the human heart. Am. J. Cardiol. 1988; 62: 24C-29C
100. Ririe DG, MacGregor DA, Butterworth J: Cardiotonic agents: what's new and useful. Seminars in Anesthesia 1994; 13: 42-49
101. Honkonen EL, Kaukinen L, Kaukinen S, Pehkonen EJ, Laippala P: Dopexamine unloads the impaired right ventricle better than iloprost, a prostacyclin analog, after coronary artery surgery. J. Cardiothorac. Vase. Anesth. 1998; 12: 647-653
102. Schmidt H, Secchi A, Wellmann R, Bach A, Bohrer H, Martin E: Dopexamine maintains intestinal villus blood flow during endotoxemia in rats. Crit. Care Med. 1996; 24: 1233-1237
103. Cain SM, Curtis SE: Systemic and regional oxygen uptake and delivery and lactate flux in endotoxic dogs infused with dopexamine. Crit. Care Med. 1991; 19: 1552-1559
104. Tighe D, Moss R, Heywood C, Al-Saady N, Webb A, Bennett D: Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Crit. Care Med. 1995; 23: 1997-2007
105. Lund N, de Asla RJ, Cladis F, Papadakos PJ, Thorborg PAJ: Dopexamine hydrochloride in septic shock: effects on oxygen delivery and oxygenation of gut, liver, and muscle. J. Trauma 1995; 38: 767-775
106. Smithies M, Yee TH, Jackson L, Beale R, Bihari D: Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit. Care Med. 1994; 22: 789-795
107. Maynard ND, Bihari DJ, Dalton RN, Smithies MN, Mason RC: Increasing splanchnic blood flow in the critically ill. Chest 1995; 108: 1648-1654
108. Boyd O, Grounds RM, Bennett ED: A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. J. Am. Med. Ass. 1993; 270: 2699-2707
109. Hannemann L, Reinhart K, Meier-Hellmann A, Wallenfang G, Bredle DL: Dopexamine hydrochloride in septic shock. Chest 1996; 109: 756-760
110. Uusaro A, Ruokonen E, Takala J: Gastric mucosal pH does not reflect changes in splanchnic blood flow after cardiac surgery. Br. J. Anaesth. 1995; 74: 149-154
111. Mines R: New cardiotonic agents. In: Barash PG (Hrsg.): ASA refresher courses in anesthesiology; 22. Aufl. Lippincott Philadelphia. 1994: 153-168
112. Geisser W, Träger K, Hähn A, Georgieff M, Ensinger H: Metabolic and calorigenic effects of dopexamine in healthy volunteers. Crit. Care Med. 1997; 25: 1332-1337
113. Fitton A, Benfield P: Dopexamine Hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 1990; 39: 308-330
114. Colucci WS, Wright RF, Braunwald E: New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments (second of two parts). N. Engl. J. Med. 1986; 314: 349-358
115. Thormann J, Kramer W, Kindler M, Kremer P, Schlepper M: Bestimmung der Wirkkomponenten von Amrinon durch kontinuierliche Analyse der Druck-Volumenbeziehungen; Anwendung der Conductance-(Volumen)-Kathetertechnik und der schnellen Laständerung durch Ballonokklusion der Vena cava inferior. Z. Kardiol. 1987; 76: 530-540
116. Scholz H, Dieterich HA, Schmitz W: Zum Mechanismus der positiven Wirkung von Phosphodiesterase-Hemmstoffen. Z. Kardiol. 1991; 80 (Suppl. 4): 1-6
117. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL: Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 1991; 325: 1468-1475
118. DiBianco R: Acute positive inotropic intervention: The phosphodiesterase inhibitors. Am. Heart J. 1991; 121: 1871-1875
119. Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey SG: Disposition of milrinone in patients after cardiac surgery. Br. J. Anaesth. 1994; 72: 426-429
120. Konstam MA, Cody RJ: Short-term use of intravenous milrinone for heart failure. Am. J. Cardiol. 1995; 75: 822-826
121. Anderson JL, Baim DS, Fein SA, Goldstein RA, LeJemtel TH, Likoff MJ: Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J. Am. Coll. Cardiol. 1987; 9: 711-722